Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Genotype-guided Targeted Agents in Combination With EZH2 Inhibitor, Zeprumetostat for Primary Refractory Peripheral T-cell Lymphoma (PTCL), a Prospective, Open-label, Multi-center Study

NCT07493330 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07493330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07493330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Genotype-guided Targeted Agents in Combination With EZH2 Inhibitor, Zeprumetostat for Primary Refractory Peripheral T-cell Lymphoma (PTCL), a Prospective, Open-label, Multi-center Study
Lead sponsor
Ruijin Hospital
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
March 23, 2026
Completion date
December 12, 2030
Enrollment
86 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ptcl, refractory